Medical Developments International (MVP) AGM 2026 summary

Opening remarks and agenda

• Mark Fladrich opened the fifth hybrid AGM after confirming a quorum; four formal resolutions followed business updates from the Chair and Interim CEO.

• Anita James attended her first AGM as Interim CEO after Brent MacGregor decided to return to the U.S. following six years leading the business.

Financial performance review

• FY26 revenue rose 9% to $42.6m; pain-management revenue increased 12% while respiratory revenue declined 15%.

• EBIT reached AUD 0.2m, up AUD 0.3m year on year; free cash flow was AUD 4.2m, up AUD 5.8m, and cash and term deposits exceeded AUD 21m.

• Australian Penthrox volumes rose 9% to 359,000 units, including 28% growth in hospitals; European in-market demand increased 18% to 382,000 units.

Board and executive committee updates

• Anita James was appointed Interim CEO for continuity; the Board will assess leadership needs and search for a permanent CEO. Brent MacGregor stepped down to return to North America after six years leading the business.

• Mark Fladrich served as Chair; directors listed included Russell Basser, Paul Townsend, Christine Emmanuel-Donnelly and Leon Hoare.

• Russell Basser and Paul Townsend stood for re-election as Non-Executive Directors; the Board recommended both candidates.